Infusion of soluble myelin basic protein protects long term against induction of experimental autoimmune encephalomyelitis

Staykova, Maria; Simmons, Rex D.; Willenborg, David O.

doi:10.1038/icb.1997.9

Cited by 11 publications

(13 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using these routes of administration, several antigens have already been used successfully in the EAE system to induce tolerance. The list includes peptides (14,15,20) or peptide derivates modified by acylation (22) or amino acid substitution (23), but also proteins (21,24) and proteinprotein (25) and immunoglobulin-protein chimeras (26). However, these experiments were usually carried out in transgenic animals, which express only the TCR specific for the peptide antigen (15,20).…”

Section: Induction and Suppression Of Eae By Epitope Multimersmentioning

confidence: 99%

Induction and Suppression of an Autoimmune Disease by Oligomerized T Cell Epitopes: Enhanced In Vivo Potency of Encephalitogenic Peptides

Falk

Rötzschke

Santambrogio

et al. 2002

Epitope Recognition Since Landsteiner’s Discovery

View full text Add to dashboard Cite

T cell epitope peptides derived from proteolipid protein (PLP139-151) or myelin basic protein (MBP86-100) induce experimental autoimmune encephalomyelitis (EAE) in "susceptible" strains of mice (e.g., SJL/J). In this study, we show that the encephalitogenic effect of these epitopes when injected subcutaneously in complete Freund's adjuvant was significantly enhanced if administered to the animal in a multimerized form as a T cell epitope oligomer (i.e., as multiple repeats of the peptide epitope, such as 16-mers). Oligomer-treated SJL/J mice developed EAE faster and showed a more severe progression of the disease than animals treated with peptide alone. In addition, haplotype-matched B10.S mice, "resistant" to EAE induction by peptide, on injection of 16-mers developed a severe form of EAE. Even more striking, however, was the dramatic suppression of incidence and severity of the disease, seen after single intravenous injections of only 50 g of the PLP139-151 16-mer, administered to SJL/J mice 7 d after the induction of the disease. Although relapse occurred at about day 45, an additional injection several days before that maintained the suppression. Importantly, the specific suppressive effect of oligomer treatment was also evident if EAE was induced with spinal cord homogenate instead of the single peptide antigen. By contrast, the PLP139-151 peptide accelerated rather than retarded the progression of disease.

show abstract

Section: Induction and Suppression Of Eae By Epitope Multimersmentioning

confidence: 99%

Induction and Suppression of an Autoimmune Disease by Oligomerized T Cell Epitopes: Enhanced In Vivo Potency of Encephalitogenic Peptides

Falk

Rötzschke

Santambrogio

et al. 2002

Epitope Recognition Since Landsteiner’s Discovery

View full text Add to dashboard Cite

show abstract

“…The range of doses included in the study was taken from those employed by other authors in the treatment of EAE with peptides [30–32], and the subcutaneous route of administration as it has been used by other groups [33,34]. We considered two treatment schedules on the assumption that in the induction phase of EAE peptide T may act by interfering with T cell activation after immunization with MBP, and in the effector phase peptide T may interfere with cytokine production by activated T cells.…”

Section: Discussionmentioning

confidence: 99%

Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats

Sáez-Torres

Espejo

Pérez

et al. 2000

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Peptide T has been shown to inhibit T cell activation and cytokine production and function. Moreover, it has been reported to be a safe treatment in humans. We have studied the ability of peptide T to prevent or ameliorate EAE in Lewis rats. Peptide T was administered subcutaneously at different doses and phases of the disease according to several treatment protocols, but we could not observe a consistent effect of peptide T ameliorating the disease. Lymph node cell proliferation and IL-4 and interferon-gamma production were also studied. We conclude that peptide T neither prevents nor ameliorates EAE in Lewis rats.

show abstract

“…There have been several reports indicating the successful suppression of EAE after i.v. administration of MOG (41–60) and MBP peptides [100] and whole MBP [101, 102]. When the MBP 82-98 peptide fragment was tested in MS patients, it generally reduced anti-MBP antibodies and significantly delayed the progression of disease in a particular sub-group of MS patients with the HLA haplotype DR2/DR4 [103].…”

Section: Peptide Treatments For Msmentioning

confidence: 99%

Immune modulating peptides for the treatment and suppression of multiple sclerosis

Badawi

Siahaan

2012

Clinical Immunology

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a neurodegenerative disease in which the immune system recognizes proteins of the myelin sheath as antigenic, thus initiating an inflammatory reaction in the central nervous system. This leads to demyelination of the axons, breakdown of the blood-brain barrier, and lesion formation. Current therapies for the treatment of MS are generally non-specific and weaken the global immune system, thus making the individual susceptible to opportunistic infections. Antigenic peptides and their derivatives are becoming more prevalent for investigation as therapeutic agents for MS because they possess immune-specific characteristics. In addition, other peptides that target vital components of the inflammatory immune response have also been developed. Therefore, the objectives of this review are to (a) summarize the immunological basis for the development of MS, (b) discuss specific and non-specific peptides tested in EAE and in humans, and (c) briefly address some problems and potential solutions with these novel therapies.

show abstract

Infusion of soluble myelin basic protein protects long term against induction of experimental autoimmune encephalomyelitis

Cited by 11 publications

References 39 publications

Induction and Suppression of an Autoimmune Disease by Oligomerized T Cell Epitopes: Enhanced In Vivo Potency of Encephalitogenic Peptides

Induction and Suppression of an Autoimmune Disease by Oligomerized T Cell Epitopes: Enhanced In Vivo Potency of Encephalitogenic Peptides

Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats

Immune modulating peptides for the treatment and suppression of multiple sclerosis

Contact Info

Product

Resources

About